The purpose of this study is to determine if MDX-1203 is safe for the treatment of renal cell carcinoma or non-hodgkin's lymphoma.

Multicenter, open-label, dose-escalation, multidose study of MDX-1203, a fully human monoclonal antibody drug conjugate targeting the CD70 transmembrane cell-surface protein which is highly expressed in ccRCC and B-NHL. MDX-1203 is composed of a human anti-CD70 monoclonal antibody covalently linked to a prodrug form of a cytotoxic deoxyribonucleic acid (DNA) minor-groove binding agent (MGBA).

The study will consist of 3 periods: Screening (up to 28 days), Treatment (up to 17 cycles or 2 years), and Follow-up (up to 6 months).

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2

• Criteria specific to each tumor type:

  • For Clear cell renal cell carcinoma (ccRCC): advanced or recurrent disease. Must have failed at least 1 prior systemic therapy
  • For B-cell non-Hodgkin's lymphoma (B-NHL): Must have failed at least 1 prior systemic therapy

• Measurable disease criteria by tumor type:

  • For ccRCC: At least 1 unidimensional measurable lesion
  • For B-NHL: At least 1 bidimensionally measurable lesion

• Prior therapies for advanced/recurrent ccRCC or relapsed/refractory B-NHL or have become intolerant to a systemic therapy

• Provide archived or fresh tumor tissue for CD70 status. Subjects must be CD70+

• Provision of fresh tissue (pre-treatment and on-treatment) for exploratory analysis is mandatory for at least 5 and a maximum of 10 B-NHL subjects

Exclusion Criteria:

• Prior therapy with an anti-CD70 antibody
• History of severe hypersensitivity reactions to other monoclonal antibodies
• Active or untreated central nervous system lymphoma
• Active infection (viral, bacterial, or fungal)
• Evidence of bleeding diathesis or coagulopathy
• Active autoimmune disease requiring immunosuppressive therapy
• Known current drug or alcohol abuse